Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Profit After Tax (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Profit After Tax for 6 consecutive years, with -$23.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Profit After Tax rose 35.85% to -$23.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$122.8 million, a 3.69% increase, with the full-year FY2025 number at -$129.8 million, down 1.78% from a year prior.
  • Profit After Tax was -$23.0 million for Q4 2025 at TScan Therapeutics, up from -$34.1 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$7.9 million in Q1 2021 to a low of -$35.8 million in Q4 2024.
  • A 5-year average of -$21.6 million and a median of -$21.1 million in 2023 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: crashed 120.36% in 2021, then soared 35.85% in 2025.
  • TScan Therapeutics' Profit After Tax stood at -$14.2 million in 2021, then crashed by 31.47% to -$18.7 million in 2022, then fell by 4.87% to -$19.6 million in 2023, then tumbled by 82.53% to -$35.8 million in 2024, then soared by 35.85% to -$23.0 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Profit After Tax are -$23.0 million (Q4 2025), -$34.1 million (Q1 2025), and -$35.8 million (Q4 2024).